Aa
A
A
Close
4043517 tn?1374010173
Drug Approved for Low Platelet Patients
http://health.yahoo.net/news/s/nm/fda-approves-glaxo-ligand-platelet-drug-for-hepatitis-c-patients

Good news for someone like myself.
Cancel
3 Answers
Page 1 of 1
1280753 tn?1367761532
i guess that's good news, but my liver doc said that there are some dangerous sides with it, and he suggested i not take it. at the time i asked him about it, the FDA had not approved it for HCV. thanks for the info.
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
446474 tn?1446351282
Promacta  (eltrombopag) has been available since 2008 for ITP and has used off label by some doctors to treat thrombocytopenia in treating low platelet counts in in hepatitis C patients doing interferon based treatment. The FDA has expanded its use now to include treating hepatitis C patients.
NOTE: Safety and efficacy have not been established in combination with direct-acting antiviral agents approved for treatment of chronic hepatitis C genotype 1 infection.

It is usually only more advanced cirrhotics with low platelet counts before starting treatment that ever need to prevent platelet counts from getting dangerously low if they treat with peg-INF. I know the Gilead's Sofobuvir taken with Ribavirin does not have this effect. And I can't see other non-peg-INF treatments from causing thrombocytopenia.

Promacta is only a temporary solution to raise platelet counts and may be used along with platelet transfusions.

Also in cirrhotics there is risk involved as Promacta can be toxic to the liver  and can cause decompensation

"BOXED WARNING

Promacta may cause hepatotoxicity. Promacta, in combination with interferon and ribavirin in patients with chronic hepatitis C, may increase the risk of hepatic decompensation. Patients receiving therapy with Promacta must have regular monitoring of serum liver tests. Discontinue Promacta if ALT levels increase to >/=3X upper limit of normal (ULN) in patients with normal liver function or >/= 3X baseline in patients with pre-treatment elevations in transaminases and are: progressive; or persistent for >/=4 weeks; or accompanied by increased direct bilirubin; or accompanied by clinical symptoms of liver injury or evidence of hepatic decompensation. Reinitiating treatment with Promacta is not recommended and should be considered only with close medical supervision and under exceptional circumstances where the potential benefit outweighs the risk."

Crossroadsec used at her transplant center.

Cheers!
Hector
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
4043517 tn?1374010173
advised by med help to respond, shot down again on any post I make regarding new treatment options, so great medhelp, I responded.
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
Your Answer
Avatar universal
Answer
Do you know how to answer? Tap here to leave your answer...
Answer
Answer
Post Answer
A
A
Recent Activity
317787 tn?1473362051
Blank
Dee1956 Meegy 180 days!! Coincidenc... Comment
8 hrs ago
Avatar universal
Blank
jimgreg on now 400 mg of lamctal,,a... Comment
Dec 09
Avatar universal
Blank
Blank
Weight Tracker
Track your weight over time
Start Tracking Now
Top Hepatitis Answerers
317787 tn?1473362051
Blank
DC
163305 tn?1333672171
Blank
Rural Mural, CA
446474 tn?1446351282
Blank
San Francisco, CA
Avatar universal
Blank
1747881 tn?1358189534
Blank
Greeley, CO
2059648 tn?1439770265
Blank
Hepatitis C Community Resources